Find policies, billing codes, payers, states, and providers

HCPCS J9273: Injection, tisotumab vedotin-tftv, 1 mg

HCPCS Level II code J9273 designates the injection of tisotumab vedotin-tftv at a unit dose of 1 mg, a targeted oncology therapeutic used in specialty cancer care. Nationally, accurate coding for this medication is important for consistent billing, benefit administration, and coverage decisions for high-cost infused or injected cancer therapies. The analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what J9273 represents clinically and operationally, typical sites of service, and which major payers are covered in the review. The publication provides benchmarks and payment context where available, summarizes recent policy and coverage considerations relevant to biologic and antibody–drug conjugate therapeutics, and outlines coding and service-line implications for outpatient oncology infusion centers. It also highlights common modifiers used with injectable drugs and notes when input data elements are not provided. Data not available in the input will be identified as such.

Customize your policy alerts

Sign up for hcpcs J9273 policy alerts

Get alerted when payer policies referencing J9273 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

HCPCS Level II code J9273 represents an injection of tisotumab vedotin-tftv, 1 mg. This billing code describes administration of the specified oncology biologic by parenteral injection. The service type is an injectable antineoplastic/targeted therapy, and the typical site of service is an outpatient infusion or oncology clinic where intravenous or subcutaneous cancer therapies are administered.

Data not available in the input.

Explore openpayer tools

View all tools

Find policies, billing codes, payers, states, and providers

HCPCS J9273: Injection, tisotumab vedotin-tftv, 1 mg

Customize your policy alerts

Sign up for hcpcs J9273 policy alerts

Get alerted when payer policies referencing J9273 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with recurrent or metastatic cervical cancer or another FDA-approved solid tumor indication for tisotumab vedotin-tftv who presents to an outpatient oncology infusion center for administration. The oncology team confirms recent clinic visit documentation supporting treatment intent, reviews baseline labs (complete blood count, liver function tests), and assesses performance status and adverse effects from prior therapy. The drug vial is reconstituted and dose calculated by weight or body surface area per manufacturer guidance; billing is reported in milligrams using HCPCS. The patient is placed in a reclined infusion chair; intravenous access is obtained via peripheral IV or implanted port. Premedication and ocular prophylaxis per protocol are administered as indicated. Tisotumab vedotin-tftv is administered by IV infusion over the required duration under direct supervision of an oncology nurse and physician. Post-infusion monitoring includes vital signs and assessment for infusion-related reactions, ocular toxicity, neuropathy, and bleeding. Documentation includes drug name J9273 with total milligrams administered, lot number, expiration, route, and site, as well as all relevant clinical monitoring and any modifier(s) applicable to billing.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered	Use when partial vial drug is discarded and payer requires reporting of wasted amount.
`JZ`	No drug was wasted/zero discarded	Use when no drug remains after preparation or all drug was fully administered.
`52`	Reduced service	Use when a reduced dose or shortened infusion is performed compared with usual practice.
`53`	Discontinued procedure	Use when infusion is started but discontinued due to patient intolerance or adverse event.
`59` is not in provided list and therefore not used	Data not available in the input.	Data not available in the input.
`78`	Unplanned return to OR by same physician following initial procedure	Rare for infusion therapy; use only if applicable for complications requiring return to OR.
`80`	Assistant surgeon	Not typically used for drug infusion; use if assistant surgeon provides distinct qualifying services during same encounter.
`62`	Two surgeons	Uncommon for infusion; use if two surgeons of different specialties perform independent services related to the encounter.
`23`	Unusual anesthesia	Use when unusual anesthesia is provided for the infusion encounter.
`22`	Increased procedural services	Use when services required are substantially greater than typically required, documented and justified.
`78`	(duplicate removed)	Data not available in the input.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology-Oncology	Medical oncologists who order and supervise systemic anticancer therapy.
`207RR0500X`	Medical Oncology	Physicians specializing in adult oncology care and infusion therapy.
`364S00000X`	Nurse Practitioner	Oncology nurse practitioners providing treatment management and supervision.
`363L00000X`	Registered Nurse	Oncology infusion nurses who administer and monitor IV therapy.
`207K00000X`	Radiation Oncology	May be involved when coordinating multimodality care; less common for drug administration.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C53.9`	Malignant neoplasm of cervix uteri, unspecified	Tisotumab vedotin-tftv is FDA-approved for recurrent or metastatic cervical cancer; this code represents typical indication.
`C53.1`	Malignant neoplasm of endocervix	Specific cervical cancer site that may be treated with systemic therapy including targeted agents.
`C79.9`	Secondary malignant neoplasm of unspecified site	Used when metastatic disease is documented as indication for systemic therapy.
`C50.919`	Malignant neoplasm of unspecified site of breast, female	Some solid tumor indications may include other primary cancers; code used if applicable per clinical indication.
`C79.31`	Secondary malignant neoplasm of brain	Represents common metastatic site coding when systemic therapy is given for metastatic disease.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, IV infusion, for initiation of therapy, up to 1 hour	Commonly used for administration time-based reporting when infusion duration fits the code definition.
`96415`	Chemotherapy administration, IV infusion, each additional hour	Used when infusion exceeds the initial hour and time-based add-on coding is required.
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	Used for some non-chemotherapeutic infusions or when chemotherapy-specific codes are not applicable.
`96401`	Chemotherapy administration, IV push, single drug	Used if a portion of therapy is given as an IV push per protocol, though most tisotumab vedotin-tftv doses are infused.
`96417`	Chemotherapy administration, additional sequential infusion of a new drug, up to 1 hour	Use when multiple sequential infusion drugs are administered during the same encounter.

Related Codes

HCPCS-J9000-DOXORUBICIN-10MG-INJECTION

HCPCS J9000: Doxorubicin Hydrochloride Injection, 10 mg

HCPCS-J9003-LEUPROLIDE-INJECTABLE-CAMCEVI-1MG

HCPCS Level II J9003: Leuprolide injectable (camcevi etm), 1 mg

HCPCS-J9010-ALEMTUZUMAB-INJECTION-10MG

HCPCS J9010: Injection, Alemtuzumab 10 mg

HCPCS-J9011-DATOPOTAMAB-DERUXTECAN-INJECTION-1MG

HCPCS Level II J9011: Injection, datopotamab deruxtecan-dlnk, 1 mg

HCPCS-J9015-ALDESLEUKIN-INJECTION-SINGLE-USE-VIAL

HCPCS J9015: Aldesleukin Injection, Single-Use Vial

HCPCS-J9017-ARSENIC-TRIOXIDE-INJECTION-1MG

HCPCS J9017: Injection, Arsenic Trioxide, 1 mg

HCPCS-J9019-ASPARAGINASE-ERWINAZE-INJECTION-1000-IU

HCPCS J9019: Asparaginase (erwinaze) Injection, 1,000 IU

HCPCS-J9020-ASPARAGINASE-INJECTION-10000-UNITS

HCPCS J9020: Injection, Asparaginase, 10,000 Units

HCPCS-J9021-ASPARAGINASE-RYLAZE-INJECTION-0-1-MG

HCPCS J9021: Injection, Asparaginase (Rylaze), 0.1 mg

HCPCS-J9022-ATEZOLIZUMAB-INJECTION-10MG

HCPCS J9022: Atezolizumab Injection, 10 mg

Showing 1–10 of 227

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered	Use when partial vial drug is discarded and payer requires reporting of wasted amount.
`JZ`	No drug was wasted/zero discarded	Use when no drug remains after preparation or all drug was fully administered.
`52`	Reduced service	Use when a reduced dose or shortened infusion is performed compared with usual practice.
`53`	Discontinued procedure	Use when infusion is started but discontinued due to patient intolerance or adverse event.
`59` is not in provided list and therefore not used	Data not available in the input.	Data not available in the input.
`78`	Unplanned return to OR by same physician following initial procedure	Rare for infusion therapy; use only if applicable for complications requiring return to OR.
`80`	Assistant surgeon	Not typically used for drug infusion; use if assistant surgeon provides distinct qualifying services during same encounter.
`62`	Two surgeons	Uncommon for infusion; use if two surgeons of different specialties perform independent services related to the encounter.
`23`	Unusual anesthesia	Use when unusual anesthesia is provided for the infusion encounter.
`22`	Increased procedural services	Use when services required are substantially greater than typically required, documented and justified.
`78`	(duplicate removed)	Data not available in the input.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology-Oncology	Medical oncologists who order and supervise systemic anticancer therapy.
`207RR0500X`	Medical Oncology	Physicians specializing in adult oncology care and infusion therapy.
`364S00000X`	Nurse Practitioner	Oncology nurse practitioners providing treatment management and supervision.
`363L00000X`	Registered Nurse	Oncology infusion nurses who administer and monitor IV therapy.
`207K00000X`	Radiation Oncology	May be involved when coordinating multimodality care; less common for drug administration.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C53.9`	Malignant neoplasm of cervix uteri, unspecified	Tisotumab vedotin-tftv is FDA-approved for recurrent or metastatic cervical cancer; this code represents typical indication.
`C53.1`	Malignant neoplasm of endocervix	Specific cervical cancer site that may be treated with systemic therapy including targeted agents.
`C79.9`	Secondary malignant neoplasm of unspecified site	Used when metastatic disease is documented as indication for systemic therapy.
`C50.919`	Malignant neoplasm of unspecified site of breast, female	Some solid tumor indications may include other primary cancers; code used if applicable per clinical indication.
`C79.31`	Secondary malignant neoplasm of brain	Represents common metastatic site coding when systemic therapy is given for metastatic disease.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, IV infusion, for initiation of therapy, up to 1 hour	Commonly used for administration time-based reporting when infusion duration fits the code definition.
`96415`	Chemotherapy administration, IV infusion, each additional hour	Used when infusion exceeds the initial hour and time-based add-on coding is required.
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	Used for some non-chemotherapeutic infusions or when chemotherapy-specific codes are not applicable.
`96401`	Chemotherapy administration, IV push, single drug	Used if a portion of therapy is given as an IV push per protocol, though most tisotumab vedotin-tftv doses are infused.
`96417`	Chemotherapy administration, additional sequential infusion of a new drug, up to 1 hour	Use when multiple sequential infusion drugs are administered during the same encounter.

Related Codes

HCPCS-J9000-DOXORUBICIN-10MG-INJECTION

HCPCS J9000: Doxorubicin Hydrochloride Injection, 10 mg

HCPCS-J9003-LEUPROLIDE-INJECTABLE-CAMCEVI-1MG

HCPCS Level II J9003: Leuprolide injectable (camcevi etm), 1 mg

HCPCS-J9010-ALEMTUZUMAB-INJECTION-10MG

HCPCS J9010: Injection, Alemtuzumab 10 mg

HCPCS-J9011-DATOPOTAMAB-DERUXTECAN-INJECTION-1MG

HCPCS Level II J9011: Injection, datopotamab deruxtecan-dlnk, 1 mg

HCPCS-J9015-ALDESLEUKIN-INJECTION-SINGLE-USE-VIAL

HCPCS J9015: Aldesleukin Injection, Single-Use Vial

HCPCS-J9017-ARSENIC-TRIOXIDE-INJECTION-1MG

HCPCS J9017: Injection, Arsenic Trioxide, 1 mg

HCPCS-J9019-ASPARAGINASE-ERWINAZE-INJECTION-1000-IU

HCPCS J9019: Asparaginase (erwinaze) Injection, 1,000 IU

HCPCS-J9020-ASPARAGINASE-INJECTION-10000-UNITS

HCPCS J9020: Injection, Asparaginase, 10,000 Units

HCPCS-J9021-ASPARAGINASE-RYLAZE-INJECTION-0-1-MG

HCPCS J9021: Injection, Asparaginase (Rylaze), 0.1 mg

HCPCS-J9022-ATEZOLIZUMAB-INJECTION-10MG

HCPCS J9022: Atezolizumab Injection, 10 mg

Showing 1–10 of 227

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.